Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
87.79 USD   -0.19%
12/07Kite and Daiichi Sankyo Announce Changes to YESCARTA« CAR T-Cell Therapy Licensing Agreement in Japan
BU
12/07Gilead Sciences, Inc. - New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
AQ
12/07Transcript : Gilead Sciences, Inc. Presents at NASDAQ 47th Investor Conference, Dec-07-2022 01:00 PM
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
87.9(c) 89.03(c) 87.98(c) 87.96(c) 87.79(c) Last
8 220 595 6 730 367 6 811 532 6 760 661 8 861 858 Volume
+0.08% +1.29% -1.18% -0.02% -0.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 26 521 M - -
Net income 2022 4 384 M - -
Net Debt 2022 15 968 M - -
P/E ratio 2022 24,4x
Yield 2022 3,32%
Sales 2023 25 466 M - -
Net income 2023 5 987 M - -
Net Debt 2023 12 130 M - -
P/E ratio 2023 18,0x
Yield 2023 3,37%
Capitalization 110 B 110 B -
EV / Sales 2022 4,75x
EV / Sales 2023 4,80x
Nbr of Employees 14 400
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.3%):... 
Sector
Pharmaceuticals
Calendar
12/07 | 08:00amPresentation
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about GILEAD SCIENCES, INC.
12/07Kite and Daiichi Sankyo Announce Changes to YESCARTA« CAR T-Cell Therapy Licensing Agre..
BU
12/07Gilead Sciences, Inc. - New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop..
AQ
12/07Transcript : Gilead Sciences, Inc. Presents at NASDAQ 47th Investor Conferenc..
CI
12/06New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in ..
BU
12/06Gilead Sciences, Inc. Announces New Data From Post-Hoc Analysis from Phase 3 TROPiCS-02..
CI
12/01Oppenheimer Adjusts Gilead Sciences Price Target to $105 From $95, Maintains Outperform..
MT
11/30FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
RE
11/30Transcript : Gilead Sciences, Inc. Presents at Piper Sandler 34th Annual Heal..
CI
11/30European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy for t..
AQ
11/29Transcript : Gilead Sciences, Inc. Presents at 5th Annual Evercore ISI Health..
CI
11/29Gilead Sciences Says EC Okays Low-Dose Tablet, Indication Extension for Biktarvy to Tre..
MT
11/29European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy« for ..
BU
11/29AstraZeneca boosts cancer portfolio with $320 mln Neogene deal
RE
11/28Gilead, Arcus Report Positive Update on Interim Analysis of Mid-Stage Lung Cancer Study
MT
11/18Factbox-Advertisers react to Twitter's new ownership
RE
More news
News in other languages on GILEAD SCIENCES, INC.
12/06Gilead Sciences, Inc. Annonce de nouvelles données issues d'une analyse post-hoc de l'é..
11/29Gilead Sciences déclare que la CE approuve le comprimé à faible dose et l'extension de ..
11/29AstraZeneca se renforce dans l'oncologie avec le rachat de Neogene Therapeutics
11/28Gilead et Arcus présentent une mise à jour positive de l'analyse intermédiaire de l'étu..
11/22Médicaments: les pénuries, symptôme d'un modèle économique qui s'essouffle
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
ETFs positioned on GILEAD SCIENCES, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD20.47%0.10%United_States
VanEck Vectors Biotech ETF - USD9.07%-1.38%United_States
Invesco Nasdaq Biotechnology ETF - USD8.13%0.80%-United_States
IShares Nasdaq US Biotechnology (D) - USD8.12%0.43%United_States
IShares Nasdaq US Biotechnology - USD8.12%0.29%United_States
More ETFs positioned on GILEAD SCIENCES, INC.
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 87,79 $
Average target price 82,25 $
Spread / Average Target -6,31%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.20.91%110 110
JOHNSON & JOHNSON2.94%463 208
ELI LILLY AND COMPANY33.42%353 438
ABBVIE INC.22.16%292 407
NOVO NORDISK A/S20.94%283 266
PFIZER, INC.-15.82%282 013